Company News »

Foundation Medicine and Collaborators to Present New Clinical Data on FoundationOne(R) Heme at the American Society of Hematology Annual Meeting

Business Wire
Share on StockTwits
Published on

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that 12 abstracts highlighting new clinical data on FoundationOne(R) Heme will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2014, at the Moscone Center in San Francisco.

FoundationOne Heme, the company’s second clinical assay developed in collaboration with Memorial Sloan Kettering Cancer Center for hematologic malignancies, sarcomas and certain pediatric cancers, provides a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials.

“We look forward to presenting new clinical data with our collaborators on FoundationOne Heme at ASH,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “We believe these data provide further evidence of the utility of Foundation Medicine’s clinical assays to help inform the treatment of patients with hematologic malignancies today and aid in the development of targeted therapies for the future.”

The schedule for oral presentations by Foundation Medicine and its collaborators is as follows:

Date & Time: Monday, December 8, 2014 at 7:45 a.m. PT
Title: Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples
Abstract number: 286
Session: 618. Acute Lymphoblastic Leukemia: Preclinical Models
Location: West Building, 3002-3004
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Monday, December 8, 2014 at 6:30 p.m. PT
Title: Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations
Abstract number: 704
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy II
Location: North Building, 120-125
Collaborator: Memorial Sloan Kettering Cancer Center

The schedule for poster presentations by Foundation Medicine and its collaborators is as follows:

Date & Time: Saturday, December 6, 2014 from 5:30-7:30 p.m. PT
Title: Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies
Abstract number: 1072
Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Location: North Building, Hall E
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Saturday, December 6, 2014 from 5:30-7:30 p.m. PT
Title: Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression
Abstract number: 1954
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I
Location: West Building, Level 1
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Saturday, December 6, 2014 from 5:30-7:30 p.m. PT
Title: Utility of Combined DNA and RNA Next-Generation Sequencing in Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice
Abstract number: 1039
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Location: North Building, Hall E
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Saturday, December 6, 2014 from 5:30-7:30 p.m. PT
Title: Genomic Alterations of Histone Modification Genes Are Significantly Less Common in Non-Hodgkin Lymphomas of Adolescents and Young Adults Compared to Older Patients
Abstract number: 1684
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I
Location: West Building, Level 1

Date & Time: Saturday, December 6, 2014 from 5:30-7:30 p.m. PT
Title: Comprehensive Hybrid Capture-Based Genomic Profiling of T-cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations
Abstract number: 1672
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I
Location: West Building, Level 1
Collaborator: Vanderbilt University Medical Center

Date & Time: Sunday, December 7, 2014 from 6:00-8:00 p.m. PT
Title: Identification of Actionable Genetic Alterations Across Different Lymphoma Histologies Using a Clinical Targeted Sequencing Assay
Abstract number: 3000
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II
Location: West Building, Level 1
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Sunday, December 7, 2014 from 6:00-8:00 p.m. PT
Title: Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma
Abstract number: 3033
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II
Location: West Building, Level 1
Collaborator: Hackensack University Medical Center

Date & Time: Sunday, December 7, 2014 from 6:00-8:00 p.m. PT
Title: A Comprehensive Clinical Next-Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies
Abstract number: 2984
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II
Location: West Building, Level 1
Collaborator: Memorial Sloan Kettering Cancer Center

Date & Time: Sunday, December 7, 2014 from 6:00-8:00 p.m. PT
Title: Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling
Abstract number: 3418
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Location: West Building, Level 1
Collaborator: University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy

Date & Time: Monday, December 8, 2014 from 6:00-8:00 p.m. PT
Title: Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
Abstract number: 4775
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Location: West Building, Level 1
Collaborator: University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy

About FoundationOne(R) Heme

FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine’s second clinical product and was developed in collaboration with Memorial Sloan Kettering Cancer Center. Using next-generation sequencing in routine cancer specimens, FoundationOne Heme interrogates all genes somatically altered in these cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions (a type of alteration that is a common driver of hematologic malignancies, sarcomas and pediatric cancers). FoundationOne Heme fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne Heme is a laboratory-developed test performed at Foundation Medicine’s CLIA-certified lab. Please visit www.FoundationOne.com for more information.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine(R) and FoundationOne(R) are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the presentation by Foundation Medicine of abstracts at American Society of Hematology (ASH) Annual Meeting and the presentation of evidence of the utility of Foundation Medicine’s clinical assays to help inform the treatment of patients with hematologic malignancies. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the evidence presented by Foundation Medicine may not demonstrate the utility of FoundationOne Heme in the treatment of hematologic malignancies and the risks described under the caption “Risk Factors” in Foundation Medicine’s Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Share on StockTwits

What others are reading on Finances

Sorry. No data so far.


Iron FX 1.11156/1.11128 2.8
XM Markets 1.09948/1.09928 2
FxPro 1.10184/1.10171 1.3
FXCM 1.13943/1.13912 3.1